Physician profile
Marc Clark
NPI 1609982081
$1,197.31
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $190 · 2021: $198 · 2022: $69.75 · 2023: $184 · 2024: $50.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.54 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.53 | 2019-2020 | |
| Celgene Corporation | $190.77 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $183.50 | 2019-2020 | |
| Janssen Biotech, INC. | $167.07 | 2019-2022 | |
| Pfizer INC. | $112.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $95.96 | 2021 | |
| Braintree Laboratories, INC. | $43.57 | 2019-2023 | Suflave, Sutab |
| Medtronic, INC. | $37.23 | 2021-2023 | Interstim |
| Intercept Pharmaceuticals, INC. | $31.12 | 2023-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.18 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.22 | 2019 | |
| Gilead Sciences, INC. | $15.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.84 | 2019 | |
| Romark Laboratories, Lc | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.